Exploring Therapeutic Approaches for Long COVID Neuropsychiatric Sequelae: Current Understanding and Potential Strategies

References (14)

1. Wilkes S. Bupropion. Drugs Today (Barc). 2006;42(10):671–681. PubMed CrossRef
2. Mazza MG, Palladini M, De Lorenzo R, et al; COVID-19 BioB Outpatient Clinic Study group. Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: Effect of inflammatory biomarkers at three-month follow-up. Brain Behav Immun. 2021;94:138–147. PubMed CrossRef
3. Reinfeld S. Can bupropion treat COVID-19-induced brain fog? a case series. Int Clin Psychopharmacol. 2023;38(3):189–191. PubMed CrossRef
4. Castanares-Zapatero D, Chalon P, Kohn L, et al. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med. 2022;54(1):1473–1487. PubMed CrossRef
5. Xia Z, DePierre JW, Nässberger L. Tricyclic antidepressants inhibit IL-6, IL-1 beta and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T cells. Immunopharmacology. 1996;34(1):27–37. PubMed CrossRef
6. Nobile B, Durand M, Olié E, et al. The anti-inflammatory effect of the tricyclic antidepressant clomipramine and its high penetration in the brain might be useful to prevent the psychiatric consequences of SARS-CoV-2 infection. Front Pharmacol. 2021;12:615695. PubMed CrossRef
7. Gonzalez-Martinez A, Guerrero-Peral ÁL, Arias-Rivas S, et al. Amitriptyline for post-COVID headache: effectiveness, tolerability, and response predictors. J Neurol. 2022;269(11):5702–5709. PubMed CrossRef
8. Wong TL, Weitzer DJ. Long COVID and Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a systemic review and comparison of clinical presentation and symptomatology. Medicina (Kaunas). 2021;57(5):418. PubMed CrossRef
9. Pliszka AG. Modafinil: a review and its potential use in the treatment of long COVID fatigue and neurocognitive deficits. Am J Psychiatry Resid J. 2022;17(4):5–7. CrossRef
10. Rabkin JG, McElhiney MC, Rabkin R, et al. Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study. J Clin Psychiatry. 2010;71(6):707–715. PubMed CrossRef
11. Zager A. Modulating the immune response with the wake-promoting drug modafinil: a potential therapeutic approach for inflammatory disorders. Brain Behav Immun. 2020;88:878–886. PubMed CrossRef
12. Li Z, You Y, Griffin N, et al. Low-dose naltrexone (LDN): a promising treatment in immune-related diseases and cancer therapy. Int Immunopharmacol. 2018;61:178–184. PubMed CrossRef
13. O’Kelly B, Vidal L, McHugh T, et al. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. Brain Behav Immun Health. 2022;24:100485. PubMed CrossRef
14. La Sala MS, Reinfeld S, Constantino E. Treatment of long-COVID neuropsychiatric sequelae using tricyclic antidepressants: a case series. J Clin Psychopharmacol. 2023;43(5):458–460. PubMed CrossRef